Eculizumab vs placebo or alternative treatmentDeath · children and adults with aHUS1 finding from 1 reviewInterventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes onlyno estimate extracted100 participantsVery low
Ravulizumab vs placebo or alternative treatmentRemission · adults with aHUS1 finding from 1 reviewInterventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes onlyno estimate extracted56 participantsVery low
Ravulizumab vs placebo or alternative treatmentChange in eGFR · adults with aHUS1 finding from 1 reviewInterventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes onlyno estimate extracted56 participantsVery low
Ravulizumab vs placebo or alternative treatmentHealth‐related quality of life · adults with aHUS1 finding from 1 reviewInterventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes onlyno estimate extracted44 participantsVery low
Ravulizumab vs placebo or alternative treatmentAdverse events · adults with aHUS1 finding from 1 reviewInterventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes onlyno estimate extracted58 participantsVery low
Ravulizumab vs placebo or alternative treatmentMeningococcal infection · adults with aHUS1 finding from 1 reviewInterventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes onlyno estimate extracted58 participantsVery low
Eculizumab vs placebo or alternative treatmentRequirement for KRT · children and adults with aHUS1 finding from 1 reviewInterventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes onlyno estimate extracted100 participantsVery low
Eculizumab vs placebo or alternative treatmentRemission · children and adults with aHUS1 finding from 1 reviewInterventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes onlyno estimate extracted100 participantsVery low
Eculizumab vs placebo or alternative treatmentChange in eGFR · children and adults with aHUS1 finding from 1 reviewInterventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes onlyno estimate extracted88 participantsVery low
Eculizumab vs placebo or alternative treatmentHealth‐related quality of life · children and adults with aHUS1 finding from 1 reviewInterventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes onlyno estimate extracted100 participantsVery low
Eculizumab vs placebo or alternative treatmentAdverse events · children and adults with aHUS1 finding from 1 reviewInterventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes onlyno estimate extracted100 participantsVery low
Eculizumab vs placebo or alternative treatmentMeningococcal infection · children and adults with aHUS1 finding from 1 reviewInterventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes onlyno estimate extracted100 participantsVery low
Ravulizumab vs placebo or alternative treatmentDeath · adults with aHUS1 finding from 1 reviewInterventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes onlyno estimate extracted58 participantsVery low
Ravulizumab vs placebo or alternative treatmentRequirement for KRT · adults with aHUS1 finding from 1 reviewInterventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes onlyno estimate extracted56 participantsVery low